Abstract
Synthetic cannabinoids (SCs) induce a pro-inflammatory condition by activating cannabinoid receptor 1 (CB(1)R) in the lungs of mice, which raises a potential therapeutic use of CB(1)R antagonists in SC-induced lung disease resulting in hospitalisation https://bit.ly/31bWw4Q.